Steve Chadban {AU} Australia

Steven Chadban

Professor Steven Chadban received the University Medal for Medicine at the University of Newcastle, NSW, completed physician training in Newcastle, Nephrology training and a PhD at Monash, Victoria, Australia. Following his PhD, Chadban completed post-doctoral studies in immunology at the University of Cambridge, UK. He led the Monash Transplantation Program from 1999–2002 then moved to Royal Prince Alfred Hospital, Sydney, Australia, where he is Stream Director of Renal Medicine and Urology, Senior Staff Nephrologist/transplant physician, Professor of Medicine and Leader of the Kidney Node, Charles Perkins Centre, University of Sydney. Professor Chadban is Past-President of the Transplantation Society of Australia and New Zealand and Councillor of The Transplantation Society, Lead Investigator in the CARSK, BEST Fluids and AusDiab Kidney Studies. Chadban advises Government as Chair of the Transplant Liason Reference Group (Organ and Tissue Authority). Co-chair of the COVID19 Rapid Response Taskforce for Donation and Transplantation, and Chair of the National Chronic Kidney Disease Expert Advisory Group (AIHW). Chadban co-chaired the 2020 KDIGO Guidelines on the evaluation of candidates for Kidney transplantation, the Global standard in kidney transplant management. Chadban is Associate Editor for Transplantation. He has spoken at numerous national and international meetings and has produced over 300 papers published in journals including the New England Journal of Medicine, JAMA, Annals, Lancet and the Journal of Clinical Investigation. His publications have been cited 18,995 times and his H-index is 67. Research interests include CKD and ESKD epidemiology, the molecular mechanisms of transplant rejection and CKD, with a focus on innate immunity and the gut microbiome, and improving outcomes for kidney transplant recipients through clinical trials. As a clinician-scientist, Chadban hopes to see lab discoveries translated into human studies and adopted into practice to improve the lives and outcomes for people with kidney disease.